BACKGROUND & AIMS: Gastrointestinal stromal tumors (GIST) are related to interstitial cells of Cajal (ICC) and often contain activating stem cell factor receptor (Kit) or platelet-derived growth factor receptor alpha (Pdgfra) mutations. Kit/Pdgfra inhibitors such as imatinib mesylate have increased progression-free survival in metastatic GIST but are not curative. In mouse models we investigated whether Kit(low) ICC progenitors could represent an inherently Kit/Pdgfra inhibitor-resistant reservoir for GIST. METHODS: Isolated Kit(low)Cd44(+)Cd34(+) cells were characterized after serial cloning. The tumorigenic potential of spontaneously transformed cells was investigated in nude mice. The Kit(low)Cd44(+)Cd34(+) cells' responsiveness to Kit activation and blockade was studied by enumerating them in Kit(K641E) mice (a GIST model), in mice with defective Kit signaling, and pharmacologically. RESULTS: Single isolated Kit(low)Cd44(+)Cd34(+) cells were clonogenic and capable of self-renewal and differentiation into ICC. In nude mice, spontaneously transformed cells formed malignant tumors expressing GIST markers. The Kit(low)Cd44(+)Cd34(+) cells were resistant to in vitro Kit blockade, including by imatinib, and occurred in normal numbers in mice with reduced Kit signaling. In Kit(K641E) mice, the mutant ICC stem cells were grossly hyperplastic but remained imatinib-resistant. In contrast, the cancer stem, cell-targeting drug salinomycin blocked the proliferation of Kit(low)Cd44(+)Cd34(+) cells and increased their sensitivity to imatinib. CONCLUSIONS: Kit(low)Cd44(+)Cd34(+) progenitors are true stem cells for normal and hyperplastic ICC and give rise to GIST. Resistance to Kit/Pdgfra inhibitors is inherent in GIST and is caused by the native ICC stem cells' lack of dependence on Kit for survival, which is maintained after the acquisition of oncogenic Kit mutation. Cancer stem cell drugs may target these cells.
BACKGROUND & AIMS:Gastrointestinal stromal tumors (GIST) are related to interstitial cells of Cajal (ICC) and often contain activating stem cell factor receptor (Kit) or platelet-derived growth factor receptor alpha (Pdgfra) mutations. Kit/Pdgfra inhibitors such as imatinib mesylate have increased progression-free survival in metastatic GIST but are not curative. In mouse models we investigated whether Kit(low) ICC progenitors could represent an inherently Kit/Pdgfra inhibitor-resistant reservoir for GIST. METHODS: Isolated Kit(low)Cd44(+)Cd34(+) cells were characterized after serial cloning. The tumorigenic potential of spontaneously transformed cells was investigated in nude mice. The Kit(low)Cd44(+)Cd34(+) cells' responsiveness to Kit activation and blockade was studied by enumerating them in Kit(K641E) mice (a GIST model), in mice with defective Kit signaling, and pharmacologically. RESULTS: Single isolated Kit(low)Cd44(+)Cd34(+) cells were clonogenic and capable of self-renewal and differentiation into ICC. In nude mice, spontaneously transformed cells formed malignant tumors expressing GIST markers. The Kit(low)Cd44(+)Cd34(+) cells were resistant to in vitro Kit blockade, including by imatinib, and occurred in normal numbers in mice with reduced Kit signaling. In Kit(K641E) mice, the mutant ICC stem cells were grossly hyperplastic but remained imatinib-resistant. In contrast, the cancer stem, cell-targeting drug salinomycin blocked the proliferation of Kit(low)Cd44(+)Cd34(+) cells and increased their sensitivity to imatinib. CONCLUSIONS:Kit(low)Cd44(+)Cd34(+) progenitors are true stem cells for normal and hyperplastic ICC and give rise to GIST. Resistance to Kit/Pdgfra inhibitors is inherent in GIST and is caused by the native ICC stem cells' lack of dependence on Kit for survival, which is maintained after the acquisition of oncogenic Kit mutation. Cancer stem cell drugs may target these cells.
Authors: S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura Journal: Science Date: 1998-01-23 Impact factor: 47.728
Authors: Tamás Ordög; Doug Redelman; Viktor J Horváth; Lisa J Miller; Burton Horowitz; Kenton M Sanders Journal: Cytometry A Date: 2004-12 Impact factor: 4.355
Authors: Brian P Rubin; Cristina R Antonescu; James P Scott-Browne; Melissa L Comstock; Yansong Gu; Munir R Tanas; Carol B Ware; Jessica Woodell Journal: Cancer Res Date: 2005-08-01 Impact factor: 12.701
Authors: B J Druker; S Tamura; E Buchdunger; S Ohno; G M Segal; S Fanning; J Zimmermann; N B Lydon Journal: Nat Med Date: 1996-05 Impact factor: 53.440
Authors: Ziyan Y Pessetto; Scott J Weir; Geetika Sethi; Melinda A Broward; Andrew K Godwin Journal: Mol Cancer Ther Date: 2013-05-08 Impact factor: 6.261
Authors: D T Asuzu; Y Hayashi; F Izbeki; L N Popko; D L Young; M R Bardsley; A Lorincz; M Kuro-O; D R Linden; G Farrugia; T Ordog Journal: Neurogastroenterol Motil Date: 2011-05-24 Impact factor: 3.598
Authors: Yujiro Hayashi; Michael R Bardsley; Yoshitaka Toyomasu; Srdjan Milosavljevic; Gabriella B Gajdos; Kyoung Moo Choi; K Marie Reid-Lombardo; Michael L Kendrick; Juliane Bingener-Casey; Chih-Min Tang; Jason K Sicklick; Simon J Gibbons; Gianrico Farrugia; Takahiro Taguchi; Anu Gupta; Brian P Rubin; Jonathan A Fletcher; Abhijit Ramachandran; Tamas Ordog Journal: Gastroenterology Date: 2015-04-09 Impact factor: 22.682
Authors: Maneesh Dave; Yujiro Hayashi; Gabriella B Gajdos; Thomas C Smyrk; Phyllis A Svingen; Sergiy M Kvasha; Andrea Lorincz; Haidong Dong; William A Faubion; Tamas Ordog Journal: Gastroenterology Date: 2015-01-28 Impact factor: 22.682
Authors: Yujiro Hayashi; Yoshitaka Toyomasu; Siva Arumugam Saravanaperumal; Michael R Bardsley; John A Smestad; Andrea Lorincz; Seth T Eisenman; Gianluca Cipriani; Molly H Nelson Holte; Fatimah J Al Khazal; Sabriya A Syed; Gabriella B Gajdos; Kyoung Moo Choi; Gary J Stoltz; Katie E Miller; Michael L Kendrick; Brian P Rubin; Simon J Gibbons; Adil E Bharucha; David R Linden; Louis James Maher; Gianrico Farrugia; Tamas Ordog Journal: Gastroenterology Date: 2017-04-21 Impact factor: 22.682